Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 25%
Buy 20%
Hold 55%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is a growing pharmaceutical company with a strong portfolio of marketed drugs and an exciting pipeline focused on both oncology and dermatology. Their partnerships with Novartis and Lilly provide valuable support and potential for further growth. Risks include potential setbacks in clinical trials and slower market uptake, but overall, the company's positive outlook and continued pipeline success make it an attractive investment opportunity.

Bears say

Incyte is facing challenges in expanding its potential market for its leading drug, Jakafi, as data from its Phase 3 study in 2L ET is only expected in late 2028 or early 2029. The company's pipeline includes promising oncology and dermatology programs, but there are concerns about the time and investment needed to bring these treatments to market. An expansion of Opzelura's EU label into moderate AD, coupled with its sales growth in the US market, may help mitigate some of these concerns and drive future revenue growth for the company.

Incyte (INCY) has been analyzed by 20 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 20% recommend Buy, 55% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 20 analysts, Incyte (INCY) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.